ID   MCCB_HUMAN              Reviewed;         563 AA.
AC   Q9HCC0; A6NIY9; Q96C27; Q9Y4L7;
DT   05-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   10-MAY-2017, entry version 159.
DE   RecName: Full=Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial;
DE            Short=MCCase subunit beta;
DE            EC=6.4.1.4;
DE   AltName: Full=3-methylcrotonyl-CoA carboxylase 2;
DE   AltName: Full=3-methylcrotonyl-CoA carboxylase non-biotin-containing subunit;
DE   AltName: Full=3-methylcrotonyl-CoA:carbon dioxide ligase subunit beta;
DE   Flags: Precursor;
GN   Name=MCCC2; Synonyms=MCCB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RA   Fukuda T., Otsuka H., Morishita R., Takemoto Y., Sone M., Nakao M.,
RA   Abe S., Kondo I.;
RT   "Human non-biotin containing subunit gene of 3-methylcrotonyl-CoA
RT   carboxylase (MCCB).";
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND
RP   VARIANTS MCC2D ARG-167 AND THR-218.
RX   PubMed=11170888; DOI=10.1086/318202;
RA   Gallardo M.E., Desviat L.R., Rodriguez J.M., Esparza-Gordillo J.,
RA   Perez-Cerda C., Perez B., Rodriguez-Pombo P., Criado O., Sanz R.,
RA   Morton D.H., Gibson K.M., Le T.P., Ribes A., Rodriguez de Cordoba S.,
RA   Ugarte M., Penalva M.A.;
RT   "The molecular basis of 3-methylcrotonylglycinuria, a disorder of
RT   leucine catabolism.";
RL   Am. J. Hum. Genet. 68:334-346(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS MCC2D GLN-99;
RP   GLN-155; LEU-173; CYS-193; ARG-310 AND MET-339.
RX   PubMed=11181649; DOI=10.1172/JCI11948;
RA   Baumgartner M.R., Almashanu S., Suormala T., Obie C., Cole R.N.,
RA   Packman S., Baumgartner E.R., Valle D.;
RT   "The molecular basis of human 3-methylcrotonyl-CoA carboxylase
RT   deficiency.";
RL   J. Clin. Invest. 107:495-504(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MCC2D THR-268.
RX   PubMed=11406611; DOI=10.1093/hmg/10.12.1299;
RA   Holzinger A., Roeschinger W., Lagler F., Mayerhofer P.U., Lichtner P.,
RA   Kattenfeld T., Thuy L.P., Nyhan W.L., Koch H.G., Muntau A.C.,
RA   Roscher A.A.;
RT   "Cloning of the human MCCA and MCCB genes and mutations therein reveal
RT   the molecular cause of 3-methylcrotonyl-CoA: carboxylase deficiency.";
RL   Hum. Mol. Genet. 10:1299-1306(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 23-28, AND SUBCELLULAR LOCATION.
RC   TISSUE=Kidney;
RX   PubMed=16023992; DOI=10.1016/j.bbrc.2005.06.190;
RA   Stadler S.C., Polanetz R., Meier S., Mayerhofer P.U., Herrmann J.M.,
RA   Anslinger K., Roscher A.A., Roschinger W., Holzinger A.;
RT   "Mitochondrial targeting signals and mature peptides of 3-
RT   methylcrotonyl-CoA carboxylase.";
RL   Biochem. Biophys. Res. Commun. 334:939-946(2005).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17360195; DOI=10.1016/j.pep.2007.01.012;
RA   Chu C.H., Cheng D.;
RT   "Expression, purification, characterization of human 3-methylcrotonyl-
RT   CoA carboxylase (MCCC).";
RL   Protein Expr. Purif. 53:421-427(2007).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 469-563.
RG   The European IMAGE consortium;
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [14]
RP   VARIANTS MCC2D ARG-190; VAL-218 AND TYR-280.
RX   PubMed=17968484; DOI=10.1007/s10038-007-0211-9;
RA   Uematsu M., Sakamoto O., Sugawara N., Kumagai N., Morimoto T.,
RA   Yamaguchi S., Hasegawa Y., Kobayashi H., Ihara K., Yoshino M.,
RA   Watanabe Y., Inokuchi T., Yokoyama T., Kiwaki K., Nakamura K.,
RA   Endo F., Tsuchiya S., Ohura T.;
RT   "Novel mutations in five Japanese patients with 3-methylcrotonyl-CoA
RT   carboxylase deficiency.";
RL   J. Hum. Genet. 52:1040-1043(2007).
RN   [15]
RP   VARIANTS MCC2D GLN-99; TRP-155; GLN-155; TYR-190; THR-268; ARG-282;
RP   ARG-310; PHE-375 AND VAL-456, AND CHARACTERIZATION OF VARIANTS TYR-190
RP   AND ARG-352.
RX   PubMed=16010683; DOI=10.1002/humu.9352;
RA   Dantas M.F., Suormala T., Randolph A., Coelho D., Fowler B., Valle D.,
RA   Baumgartner M.R.;
RT   "3-Methylcrotonyl-CoA carboxylase deficiency: mutation analysis in 28
RT   probands, 9 symptomatic and 19 detected by newborn screening.";
RL   Hum. Mutat. 26:164-174(2005).
RN   [16]
RP   VARIANTS MCC2D PHE-355; ARG-477; ARG-517 AND SER-520.
RX   PubMed=21071250; DOI=10.1016/j.ymgme.2010.10.008;
RA   Nguyen K.V., Naviaux R.K., Patra S., Barshop B.A., Nyhan W.L.;
RT   "Novel mutations in the human MCCA and MCCB gene causing
RT   methylcrotonylglycinuria.";
RL   Mol. Genet. Metab. 102:218-221(2011).
RN   [17]
RP   VARIANTS MCC2D TYR-280 AND SER-459.
RX   PubMed=22150417; DOI=10.1111/j.1399-0004.2011.01704.x;
RA   Cho S.Y., Park H.D., Lee Y.W., Ki C.S., Lee S.Y., Sohn Y.B.,
RA   Park S.W., Kim S.H., Ji S., Kim S.J., Choi E.W., Kim C.H., Ko A.R.,
RA   Paik K.H., Lee D.H., Jin D.K.;
RT   "Mutational spectrum in eight Korean patients with 3-methylcrotonyl-
RT   CoA carboxylase deficiency.";
RL   Clin. Genet. 81:96-98(2012).
RN   [18]
RP   VARIANTS MCC2D VAL-218; MET-339 AND GLY-523.
RX   PubMed=22264772; DOI=10.1016/j.ymgme.2011.12.018;
RA   Morscher R.J., Grunert S.C., Burer C., Burda P., Suormala T.,
RA   Fowler B., Baumgartner M.R.;
RT   "A single mutation in MCCC1 or MCCC2 as a potential cause of positive
RT   screening for 3-methylcrotonyl-CoA carboxylase deficiency.";
RL   Mol. Genet. Metab. 105:602-606(2012).
RN   [19]
RP   VARIANTS MCC2D PHE-39; GLN-99; PHE-101; GLY-118 DEL; PHE-131; ASN-146;
RP   THR-152; TRP-155; ARG-167; ASP-169; LEU-173; ARG-190; TYR-190;
RP   CYS-193; HIS-193; ASN-200; THR-218; VAL-218; GLU-220; LEU-224;
RP   ASP-237; LEU-266; TYR-280; ARG-282; ARG-310; MET-339; VAL-340 ARG-352;
RP   PHE-355; PHE-375; THR-403; LEU-434; VAL-456; ARG-475; ARG-477;
RP   ARG-517; SER-520; GLY-523 AND GLU-555, AND CHARACTERIZATION OF
RP   VARIANTS MCC2D PHE-39; GLY-118 DEL; ASN-146; ARG-282; LEU-434;
RP   VAL-456; ARG-475 AND GLY-523.
RX   PubMed=22642865; DOI=10.1186/1750-1172-7-31;
RA   Gruenert S.C., Stucki M., Morscher R.J., Suormala T., Buerer C.,
RA   Burda P., Christensen E., Ficicioglu C., Herwig J., Koelker S.,
RA   Moeslinger D., Pasquini E., Santer R., Schwab K.O., Wilcken B.,
RA   Fowler B., Yue W.W., Baumgartner M.R.;
RT   "3-methylcrotonyl-CoA carboxylase deficiency: clinical, biochemical,
RT   enzymatic and molecular studies in 88 individuals.";
RL   Orphanet J. Rare Dis. 7:31-54(2012).
RN   [20]
RP   VARIANTS MCC2D ILE-139 AND ARG-319.
RX   PubMed=25382614; DOI=10.1111/cge.12535;
RA   Yang L., Yang J., Zhang T., Weng C., Hong F., Tong F., Yang R.,
RA   Yin X., Yu P., Huang X., Qi M.;
RT   "Identification of eight novel mutations and transcript analysis of
RT   two splicing mutations in Chinese newborns with MCC deficiency.";
RL   Clin. Genet. 88:484-488(2015).
RN   [21]
RP   VARIANTS MCC2D VAL-68; ARG-105; TRP-155; ASP-163; ASN-200; ALA-214;
RP   TRP-216; THR-218; ASP-230; CYS-318; MET-339; VAL-387; PRO-393;
RP   ARG-410; ASP-410; THR-441; VAL-461; ARG-475 AND THR-524.
RX   PubMed=27601257; DOI=10.1016/j.gene.2016.09.003;
RA   Fonseca H., Azevedo L., Serrano C., Sousa C., Marcao A., Vilarinho L.;
RT   "3-Methylcrotonyl-CoA carboxylase deficiency: Mutational spectrum
RT   derived from comprehensive newborn screening.";
RL   Gene 594:203-210(2016).
CC   -!- FUNCTION: Carboxyltransferase subunit of the 3-methylcrotonyl-CoA
CC       carboxylase, an enzyme that catalyzes the conversion of 3-
CC       methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a critical step for
CC       leucine and isovaleric acid catabolism.
CC       {ECO:0000269|PubMed:17360195}.
CC   -!- CATALYTIC ACTIVITY: ATP + 3-methylcrotonoyl-CoA + HCO(3)(-) = ADP
CC       + phosphate + 3-methylglutaconyl-CoA.
CC       {ECO:0000269|PubMed:17360195}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=45 uM for ATP {ECO:0000269|PubMed:17360195};
CC         KM=74 uM for 3-methylcrotonyl-CoA {ECO:0000269|PubMed:17360195};
CC         Note=kcat is 4.0 sec(-1).;
CC   -!- PATHWAY: Amino-acid degradation; L-leucine degradation; (S)-3-
CC       hydroxy-3-methylglutaryl-CoA from 3-isovaleryl-CoA: step 2/3.
CC   -!- SUBUNIT: Probably a dodecamer composed of six biotin-containing
CC       alpha subunits (MCCC1) and six beta (MCCC2) subunits.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix
CC       {ECO:0000269|PubMed:11170888, ECO:0000269|PubMed:16023992}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9HCC0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9HCC0-2; Sequence=VSP_000069;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: 3-methylcrotonoyl-CoA carboxylase 2 deficiency (MCC2D)
CC       [MIM:210210]: An autosomal recessive disorder of leucine
CC       catabolism. The phenotype is variable, ranging from neonatal onset
CC       with severe neurological involvement to asymptomatic adults. There
CC       is a characteristic organic aciduria with massive excretion of 3-
CC       hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in
CC       combination with a severe secondary carnitine deficiency.
CC       {ECO:0000269|PubMed:11170888, ECO:0000269|PubMed:11181649,
CC       ECO:0000269|PubMed:11406611, ECO:0000269|PubMed:16010683,
CC       ECO:0000269|PubMed:17968484, ECO:0000269|PubMed:21071250,
CC       ECO:0000269|PubMed:22150417, ECO:0000269|PubMed:22264772,
CC       ECO:0000269|PubMed:22642865, ECO:0000269|PubMed:25382614,
CC       ECO:0000269|PubMed:27601257}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the AccD/PCCB family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH14897.1; Type=Frameshift; Positions=359; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB050049; BAB16880.1; -; mRNA.
DR   EMBL; AB050050; BAB41121.1; -; Genomic_DNA.
DR   EMBL; AF310971; AAG53094.1; -; mRNA.
DR   EMBL; AF301000; AAK16404.1; -; mRNA.
DR   EMBL; AF261884; AAK49409.1; -; mRNA.
DR   EMBL; AC138832; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471084; EAW95693.1; -; Genomic_DNA.
DR   EMBL; BC014897; AAH14897.1; ALT_FRAME; mRNA.
DR   EMBL; BC065027; AAH65027.1; -; mRNA.
DR   EMBL; AL079298; CAB45194.1; -; mRNA.
DR   CCDS; CCDS34184.1; -. [Q9HCC0-1]
DR   RefSeq; NP_071415.1; NM_022132.4. [Q9HCC0-1]
DR   RefSeq; XP_005248624.1; XM_005248567.1. [Q9HCC0-2]
DR   UniGene; Hs.604789; -.
DR   ProteinModelPortal; Q9HCC0; -.
DR   SMR; Q9HCC0; -.
DR   BioGrid; 122050; 35.
DR   IntAct; Q9HCC0; 19.
DR   MINT; MINT-8051924; -.
DR   STRING; 9606.ENSP00000343657; -.
DR   DrugBank; DB00121; Biotin.
DR   iPTMnet; Q9HCC0; -.
DR   PhosphoSitePlus; Q9HCC0; -.
DR   BioMuta; MCCC2; -.
DR   DMDM; 20138731; -.
DR   REPRODUCTION-2DPAGE; IPI00784044; -.
DR   EPD; Q9HCC0; -.
DR   MaxQB; Q9HCC0; -.
DR   PaxDb; Q9HCC0; -.
DR   PeptideAtlas; Q9HCC0; -.
DR   PRIDE; Q9HCC0; -.
DR   Ensembl; ENST00000340941; ENSP00000343657; ENSG00000131844. [Q9HCC0-1]
DR   GeneID; 64087; -.
DR   KEGG; hsa:64087; -.
DR   UCSC; uc003kbs.5; human. [Q9HCC0-1]
DR   CTD; 64087; -.
DR   DisGeNET; 64087; -.
DR   GeneCards; MCCC2; -.
DR   HGNC; HGNC:6937; MCCC2.
DR   HPA; HPA038300; -.
DR   HPA; HPA038301; -.
DR   HPA; HPA061546; -.
DR   MalaCards; MCCC2; -.
DR   MIM; 210210; phenotype.
DR   MIM; 609014; gene.
DR   neXtProt; NX_Q9HCC0; -.
DR   OpenTargets; ENSG00000131844; -.
DR   Orphanet; 6; Isolated 3-methylcrotonyl-CoA carboxylase deficiency.
DR   PharmGKB; PA30681; -.
DR   eggNOG; KOG0540; Eukaryota.
DR   eggNOG; COG4799; LUCA.
DR   GeneTree; ENSGT00530000063337; -.
DR   HOGENOM; HOG000218692; -.
DR   HOVERGEN; HBG052424; -.
DR   InParanoid; Q9HCC0; -.
DR   KO; K01969; -.
DR   OMA; QCIVVAN; -.
DR   OrthoDB; EOG091G05B5; -.
DR   PhylomeDB; Q9HCC0; -.
DR   TreeFam; TF300446; -.
DR   BioCyc; MetaCyc:ENSG00000131844-MONOMER; -.
DR   Reactome; R-HSA-196780; Biotin transport and metabolism.
DR   Reactome; R-HSA-3371599; Defective HLCS causes multiple carboxylase deficiency.
DR   Reactome; R-HSA-70895; Branched-chain amino acid catabolism.
DR   UniPathway; UPA00363; UER00861.
DR   GenomeRNAi; 64087; -.
DR   PRO; PR:Q9HCC0; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000131844; -.
DR   CleanEx; HS_MCCC2; -.
DR   ExpressionAtlas; Q9HCC0; baseline and differential.
DR   Genevisible; Q9HCC0; HS.
DR   GO; GO:0002169; C:3-methylcrotonyl-CoA carboxylase complex, mitochondrial; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:1905202; C:methylcrotonoyl-CoA carboxylase complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005759; C:mitochondrial matrix; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004485; F:methylcrotonoyl-CoA carboxylase activity; IEA:UniProtKB-EC.
DR   GO; GO:0006768; P:biotin metabolic process; TAS:Reactome.
DR   GO; GO:0009083; P:branched-chain amino acid catabolic process; TAS:Reactome.
DR   GO; GO:0015936; P:coenzyme A metabolic process; IEA:Ensembl.
DR   GO; GO:0006552; P:leucine catabolic process; TAS:UniProtKB.
DR   GO; GO:0051291; P:protein heterooligomerization; NAS:ParkinsonsUK-UCL.
DR   InterPro; IPR034733; AcCoA_carboxyl.
DR   InterPro; IPR029045; ClpP/crotonase-like_dom.
DR   InterPro; IPR011763; COA_CT_C.
DR   InterPro; IPR011762; COA_CT_N.
DR   Pfam; PF01039; Carboxyl_trans; 1.
DR   SUPFAM; SSF52096; SSF52096; 2.
DR   PROSITE; PS50989; COA_CT_CTER; 1.
DR   PROSITE; PS50980; COA_CT_NTER; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Ligase; Mitochondrion;
KW   Nucleotide-binding; Reference proteome; Transit peptide.
FT   TRANSIT       1     22       Mitochondrion.
FT                                {ECO:0000269|PubMed:16023992}.
FT   CHAIN        23    563       Methylcrotonoyl-CoA carboxylase beta
FT                                chain, mitochondrial.
FT                                /FTId=PRO_0000000291.
FT   DOMAIN       49    306       CoA carboxyltransferase N-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01136}.
FT   DOMAIN      309    555       CoA carboxyltransferase C-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01137}.
FT   REGION       49    555       Carboxyltransferase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01138}.
FT   REGION      343    372       Acyl-CoA binding. {ECO:0000255}.
FT   MOD_RES      70     70       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q3ULD5}.
FT   MOD_RES      70     70       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q3ULD5}.
FT   MOD_RES     141    141       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q3ULD5}.
FT   MOD_RES     495    495       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q3ULD5}.
FT   MOD_RES     495    495       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q3ULD5}.
FT   MOD_RES     511    511       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q3ULD5}.
FT   VAR_SEQ     209    246       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_000069.
FT   VARIANT      39     39       S -> F (in MCC2D; has some wild-type
FT                                residual activity; dbSNP:rs398124371).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072507.
FT   VARIANT      68     68       G -> V (in MCC2D; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077291.
FT   VARIANT      99     99       E -> Q (in MCC2D; severe and mild form;
FT                                dbSNP:rs28934883).
FT                                {ECO:0000269|PubMed:11181649,
FT                                ECO:0000269|PubMed:16010683,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_012792.
FT   VARIANT     101    101       S -> F (in MCC2D; dbSNP:rs748028684).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072508.
FT   VARIANT     105    105       G -> R (in MCC2D; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077292.
FT   VARIANT     118    118       Missing (in MCC2D; has some wild-type
FT                                residual activity).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072509.
FT   VARIANT     131    131       C -> F (in MCC2D).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072510.
FT   VARIANT     139    139       T -> I (in MCC2D).
FT                                {ECO:0000269|PubMed:25382614}.
FT                                /FTId=VAR_077293.
FT   VARIANT     146    146       Y -> N (in MCC2D; has some wild-type
FT                                residual activity).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072511.
FT   VARIANT     152    152       K -> T (in MCC2D).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072512.
FT   VARIANT     155    155       R -> Q (in MCC2D; mild form;
FT                                dbSNP:rs119103220).
FT                                {ECO:0000269|PubMed:11181649,
FT                                ECO:0000269|PubMed:16010683}.
FT                                /FTId=VAR_012793.
FT   VARIANT     155    155       R -> W (in MCC2D; dbSNP:rs141030969).
FT                                {ECO:0000269|PubMed:16010683,
FT                                ECO:0000269|PubMed:22642865,
FT                                ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_072513.
FT   VARIANT     163    163       N -> D (in MCC2D; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077294.
FT   VARIANT     167    167       C -> R (in MCC2D; dbSNP:rs28934884).
FT                                {ECO:0000269|PubMed:11170888,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_012794.
FT   VARIANT     169    169       Y -> D (in MCC2D).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072514.
FT   VARIANT     173    173       S -> L (in MCC2D; severe form;
FT                                dbSNP:rs752866557).
FT                                {ECO:0000269|PubMed:11181649,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_012795.
FT   VARIANT     190    190       H -> R (in MCC2D; dbSNP:rs119103225).
FT                                {ECO:0000269|PubMed:17968484,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072515.
FT   VARIANT     190    190       H -> Y (in MCC2D; produces severely
FT                                decreased wild-type residual activity;
FT                                dbSNP:rs773774134).
FT                                {ECO:0000269|PubMed:16010683,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072516.
FT   VARIANT     193    193       R -> C (in MCC2D; mild form;
FT                                dbSNP:rs547662164).
FT                                {ECO:0000269|PubMed:11181649,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_012796.
FT   VARIANT     193    193       R -> H (in MCC2D; dbSNP:rs535519604).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072517.
FT   VARIANT     200    200       I -> N (in MCC2D; dbSNP:rs140806722).
FT                                {ECO:0000269|PubMed:22642865,
FT                                ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_072518.
FT   VARIANT     214    214       G -> A (in MCC2D; dbSNP:rs277995).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077295.
FT   VARIANT     216    216       C -> W (in MCC2D).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077296.
FT   VARIANT     218    218       A -> T (in MCC2D).
FT                                {ECO:0000269|PubMed:11170888,
FT                                ECO:0000269|PubMed:22642865,
FT                                ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_012797.
FT   VARIANT     218    218       A -> V (in MCC2D; dbSNP:rs760420191).
FT                                {ECO:0000269|PubMed:17968484,
FT                                ECO:0000269|PubMed:22264772,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072519.
FT   VARIANT     220    220       G -> E (in MCC2D).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072520.
FT   VARIANT     224    224       P -> L (in MCC2D).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072521.
FT   VARIANT     230    230       N -> D (in MCC2D; dbSNP:rs766753795).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077297.
FT   VARIANT     237    237       G -> D (in MCC2D).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072522.
FT   VARIANT     266    266       H -> L (in MCC2D).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072523.
FT   VARIANT     268    268       R -> T (in MCC2D; asymptomatic form;
FT                                dbSNP:rs119103223).
FT                                {ECO:0000269|PubMed:11406611,
FT                                ECO:0000269|PubMed:16010683}.
FT                                /FTId=VAR_012798.
FT   VARIANT     268    268       Missing (in MCC2D).
FT                                {ECO:0000269|PubMed:16010683}.
FT                                /FTId=VAR_072524.
FT   VARIANT     280    280       D -> Y (in MCC2D; dbSNP:rs119103226).
FT                                {ECO:0000269|PubMed:17968484,
FT                                ECO:0000269|PubMed:22150417,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_067199.
FT   VARIANT     282    282       H -> R (in MCC2D; has some wild-type
FT                                residual activity).
FT                                {ECO:0000269|PubMed:16010683,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072525.
FT   VARIANT     310    310       P -> R (in MCC2D; mild form;
FT                                dbSNP:rs119103221).
FT                                {ECO:0000269|PubMed:11181649,
FT                                ECO:0000269|PubMed:16010683,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_012799.
FT   VARIANT     318    318       Y -> C (in MCC2D; dbSNP:rs773115035).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077298.
FT   VARIANT     319    319       G -> R (in MCC2D).
FT                                {ECO:0000269|PubMed:25382614}.
FT                                /FTId=VAR_077299.
FT   VARIANT     339    339       V -> M (in MCC2D; severe form;
FT                                dbSNP:rs150591260).
FT                                {ECO:0000269|PubMed:11181649,
FT                                ECO:0000269|PubMed:22264772,
FT                                ECO:0000269|PubMed:22642865,
FT                                ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_012800.
FT   VARIANT     340    340       D -> V (in MCC2D; dbSNP:rs398124370).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072526.
FT   VARIANT     352    352       G -> R (in MCC2D; produces severely
FT                                decreased wild-type residual activity;
FT                                dbSNP:rs765438239).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072527.
FT   VARIANT     355    355       L -> F (in MCC2D; dbSNP:rs757052602).
FT                                {ECO:0000269|PubMed:21071250,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072528.
FT   VARIANT     375    375       V -> F (in MCC2D).
FT                                {ECO:0000269|PubMed:16010683,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072529.
FT   VARIANT     387    387       F -> V (in MCC2D; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077300.
FT   VARIANT     393    393       Q -> P (in MCC2D).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077301.
FT   VARIANT     403    403       N -> T (in MCC2D).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072530.
FT   VARIANT     410    410       G -> D (in MCC2D; dbSNP:rs771440617).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077302.
FT   VARIANT     410    410       G -> R (in MCC2D).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077303.
FT   VARIANT     434    434       V -> L (in MCC2D; has some wild-type
FT                                residual activity; dbSNP:rs758506791).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072531.
FT   VARIANT     437    437       I -> V (in MCC2D; mild form;
FT                                dbSNP:rs119103224).
FT                                /FTId=VAR_012801.
FT   VARIANT     441    441       I -> T (in MCC2D; unknown pathological
FT                                significance; dbSNP:rs139852818).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077304.
FT   VARIANT     456    456       A -> V (in MCC2D; shows virtually no
FT                                enzyme activity; dbSNP:rs727504011).
FT                                {ECO:0000269|PubMed:16010683,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072532.
FT   VARIANT     459    459       P -> S (in MCC2D; dbSNP:rs754741111).
FT                                {ECO:0000269|PubMed:22150417}.
FT                                /FTId=VAR_067200.
FT   VARIANT     461    461       F -> V (in MCC2D).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077305.
FT   VARIANT     475    475       G -> R (in MCC2D; has some wild-type
FT                                residual activity; dbSNP:rs148773718).
FT                                {ECO:0000269|PubMed:22642865,
FT                                ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_072533.
FT   VARIANT     477    477       Q -> R (in MCC2D; dbSNP:rs769558016).
FT                                {ECO:0000269|PubMed:21071250,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072534.
FT   VARIANT     478    478       A -> G (in dbSNP:rs35068278).
FT                                /FTId=VAR_038630.
FT   VARIANT     517    517       G -> R (in MCC2D).
FT                                {ECO:0000269|PubMed:21071250,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072535.
FT   VARIANT     520    520       Y -> S (in MCC2D; dbSNP:rs150327768).
FT                                {ECO:0000269|PubMed:21071250,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072536.
FT   VARIANT     523    523       S -> G (in MCC2D; has some wild-type
FT                                residual activity).
FT                                {ECO:0000269|PubMed:22264772,
FT                                ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072537.
FT   VARIANT     524    524       A -> T (in MCC2D; dbSNP:rs774241918).
FT                                {ECO:0000269|PubMed:27601257}.
FT                                /FTId=VAR_077306.
FT   VARIANT     555    555       K -> E (in MCC2D).
FT                                {ECO:0000269|PubMed:22642865}.
FT                                /FTId=VAR_072538.
SQ   SEQUENCE   563 AA;  61333 MW;  8E3D401AF52DC7D2 CRC64;
     MWAVLRLALR PCARASPAGP RAYHGDSVAS LGTQPDLGSA LYQENYKQMK ALVNQLHERV
     EHIKLGGGEK ARALHISRGK LLPRERIDNL IDPGSPFLEL SQFAGYQLYD NEEVPGGGII
     TGIGRVSGVE CMIIANDATV KGGAYYPVTV KKQLRAQEIA MQNRLPCIYL VDSGGAYLPR
     QADVFPDRDH FGRTFYNQAI MSSKNIAQIA VVMGSCTAGG AYVPAMADEN IIVRKQGTIF
     LAGPPLVKAA TGEEVSAEDL GGADLHCRKS GVSDHWALDD HHALHLTRKV VRNLNYQKKL
     DVTIEPSEEP LFPADELYGI VGANLKRSFD VREVIARIVD GSRFTEFKAF YGDTLVTGFA
     RIFGYPVGIV GNNGVLFSES AKKGTHFVQL CCQRNIPLLF LQNITGFMVG REYEAEGIAK
     DGAKMVAAVA CAQVPKITLI IGGSYGAGNY GMCGRAYSPR FLYIWPNARI SVMGGEQAAN
     VLATITKDQR AREGKQFSSA DEAALKEPII KKFEEEGNPY YSSARVWDDG IIDPADTRLV
     LGLSFSAALN APIEKTDFGI FRM
//
